Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.08.052 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Rohan Salunkhe und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Radiosurgery, Organs at Risk, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ontario Institute for Cancer Research, London Health Sciences Foundation.
Abstract (Originalsprache)
PURPOSE: The Stereotactic Radiation Therapy for Ultra-Central Non-Small Cell Lung Cancer: Safety and Efficacy Trial (SUNSET) trial investigated the maximum tolerated dose for ultracentral lung tumors treated with stereotactic body radiation therapy. Here, we report a spatial and dosimetric secondary analysis of the treatment plans and assess relationships between doses to targets, organs at risk (OARs), and clinical outcomes. METHODS AND MATERIALS: Five institutions enrolled patients with ultracentral lung cancer, cT1-3N0M0, and all received 60 Gy in 8 fractions. Maximum dose was limited to 120% of prescription. Planning data sets and treatment plans were imported into a central repository. Univariable logistic and Cox proportional hazards regression modeling were performed to identify significant dosimetric predictors for related grade ≥2 adverse events, overall survival, and local control (LC). RESULTS: Thirty patients were included in this analysis. At median follow-up of 36.5 months, 11 patients experienced grade ≥2 toxicity. The planning target volume (PTV) overlapped with 58 central OARs of which airway was most common (n = 26). The mean maximum dose was 69.3 Gy (range, 63.8-72.0 Gy); all were within the internal target volume. Mean ± SD PTV D98 was 56.1 ± 7.8 Gy, whereas D0.1 cm3 of proximal bronchial tree, esophagus, and pulmonary artery were 53.1 ± 12.6 Gy, 26.5 ± 10.5 Gy, and 57.0 ± 8.6 Gy, respectively. On regression analysis, the combined overlap volume (cm3) of the 2 primary overlapping OARs with PTV was associated with inferior LC (hazard ratio [HR], 2.86; P = .012); however, it was not associated with increase in grade ≥2 adverse events (odds ratio, 1.17; P = .49). There was no association between OAR doses (D1 cm3 and D0.1 cm3) with toxicity. PTV undercoverage (D98) was not associated with worse LC (HR per 5 Gy, 1.54; P = .68); however, lower PTV coverage was significantly associated with reduced overall survival for D98 (HR, 0.65; P = .014) and D95 (HR per 5 Gy, 0.66; P = .035). CONCLUSIONS: Within the dose constraints used in the trial, there was no relationship identified between OAR doses and toxicity. LC decreased with increasing overlap of PTV with OARs; however, this was not associated with dosimetric undercoverage of the target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
- Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.
- Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Department of Radiation Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
Förderung
- Ontario Institute for Cancer Research
- London Health Sciences Foundation
Zitieren
APA
Salunkhe, R., Palma, D. A., Warner, A., Bahig, H., Laba, J. M., Lang, P., Rodrigues, G. B., Campeau, M. P., Faria, S., Duclos, M., Thuc Toni Vu, T. T., Lok, B. H., Raman, S., Louie, A. V., Hope, A., Bezjak, A., Bratman, S. V., Swaminath, A., Kundapur, V., …, & Giuliani, M. E. (2025). Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.08.052
Vancouver
Salunkhe R, Palma DA, Warner A, Bahig H, Laba JM, Lang P, et al. Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.08.052
BibTeX
@article{Salunkhe2025,
author = {Salunkhe, Rohan and Palma, David A and Warner, Andrew and Bahig, Houda and Laba, Joanna M and Lang, Pencilla and Rodrigues, George B and Campeau, Marie-Pierre and Faria, Sergio and Duclos, Marie and Thuc Toni Vu, Thi Trinh and Lok, Benjamin H and Raman, Srinivas and Louie, Alexander V and Hope, Andrew and Bezjak, Andrea and Bratman, Scott V and Swaminath, Anand and Kundapur, Vijayananda and Doucet, Robert and Ruo, Russel and Keller, Brian M and Wierzbicki, Marcin and Drever, Laura and Gaede, Stewart and Bissonnette, Jean-Pierre and Giuliani, Meredith E},
title = {Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.08.052}
}
EUVIMED